

**Anthrax Lethal Factor (LF-HMA),
Recombinant from *Bacillus anthracis***

Catalog No. NR-4368

This reagent is the property of the U.S. Government

For research use only. Not for human use.

Contributor:

BEI Resources

Manufacturer:

List Biological Laboratories, Inc.

Product Description:

Recombinant anthrax lethal factor (LF, 90 kDa) was produced using a plasmid licensed from the NIH.^{1,2} The plasmid contains the coding sequences for two additional amino acids, a histidine (H) and a methionine (M), beyond the native N-terminal alanine (A). The lethal factor produced from this plasmid has recently been designated LF-HMA by the manufacturer. The plasmid was introduced into a non-sporulating, avirulent strain of *Bacillus anthracis* lacking both of the wild type plasmids, pX01 and pX02. Recombinant LF-HMA was purified using conventional chromatographic techniques. The resulting purified protein lacks all other anthrax virulence factors.

A recombinant form of the LF protein containing the native alanine at the N-terminus³, also produced in *Bacillus anthracis*, is available as BEI Resources NR-28544. This form of the protein has been designated LF-A by the manufacturer. LF-HMA has been reported to have 3-fold lower potency than LF-A in cell culture cytotoxicity assays and in rat lethality studies.³

LF is a zinc-dependent metalloprotease which cleaves the amino terminus of signaling proteins of the mitogen-activated protein kinase family (MAPKK), destroying their ability to signal. *In vivo*, recombinant LF binds to a cleaved form of recombinant protective antigen (PA), and is transported by PA into the cytosol of the macrophage where LF exerts its pathogenic effect.

Material Provided:

Each vial contains approximately 0.75 mg (lyophilized) of recombinant LF-HMA from *Bacillus anthracis*. After reconstitution with 1 mL of sterile water, the buffer concentration is 5 mM HEPES (pH 7.5) and 50 mM NaCl. Note: Handle the product gently. DO NOT VORTEX.

Packaging and Storage:

This product was packaged aseptically, lyophilized and sealed under vacuum. The product is provided at room temperature and should be stored at 2°C to 8°C prior to reconstitution.

Reconstitution and Storage:

Recombinant anthrax LF-HMA in 5 mM HEPES (pH 7.5) and 50 mM NaCl is stable for a few hours at 2°C to 8°C. Longer periods of time at 2°C to 8°C will result in a decline in the activity of PA-LF complex in living cells.

To enhance stability and recovery, reconstitution at 1 mg/mL¹ in the presence of 1 mg/mL bovine serum albumin (BSA) is recommended. Under these conditions, storage for a period of two weeks at 2°C to 8°C may be acceptable for some applications.

For optimal long-term storage, aliquoting and freezing the material at -20°C or colder is recommended. Repeated freeze-thaw cycles should be avoided. Glycerol may be added to 50% if a liquid is desired at freezer temperatures.

Tissue Culture Application:

Tissue culture media containing glutamate must be fresh. Ammonium ion released when glutamate breaks down may prevent acidification of the endosome thereby inhibiting translocation of LF or edema factor (EF) into the cytosol.² A stable form of glutamate may be used.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Anthrax Lethal Factor (LF-HMA), Recombinant from *Bacillus anthracis*, NR-4368."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible

for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

References:

1. Leppla, S. H. "Production and Purification of Anthrax Toxin." Methods Enzymol. 165 (1988): 103-116. PubMed: 3148094.
2. Stephen Little, personal communication.
3. Gupta, P. K., et al. "Role of N-Terminal Amino Acids in the Potency of Anthrax Lethal Factor." PLoS One 3 (2008): e3130. PubMed: 18769623.

ATCC® is a trademark of the American Type Culture Collection.

